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Abstract
Antibiotic-associated diarrhea (AAD) and Clostridum 
difficile  infections (CDI) have been well studied for 
adult cases, but not as well in the pediatric population. 
Whether the disease process or response to treat-
ments differs between pediatric and adult patients is 
an important clinical concern when following global 
guidelines based largely on adult patients. A systematic 
review of the literature using databases PubMed 
(June 3, 1978-2015) was conducted to compare 
AAD and CDI in pediatric and adult populations and 
determine significant differences and similarities 
that might impact clinical decisions. In general, 
pediatric AAD and CDI have a more rapid onset of 
symptoms, a shorter duration of disease and fewer 
CDI complications (required surgeries and extended 
hospitalizations) than in adults. Children experience 
more community-associated CDI and are associated 
with smaller outbreaks than adult cases of CDI. The 
ribotype NAP1/027/BI is more common in adults than 
children. Children and adults share some similar risk 
factors, but adults have more complex risk factor 
profiles associated with more co-morbidities, types of 
disruptive factors and a wider range of exposures to C. 
difficile  in the healthcare environment. The treatment 
of pediatric and adult AAD is similar (discontinuing or 
switching the inciting antibiotic), but other treatment 
strategies for AAD have not been established. Pediatric 
CDI responds better to metronidazole, while adult CDI 
responds better to vancomycin. Recurrent CDI is not 
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commonly reported for children. Prevention for both 
pediatric and adult AAD and CDI relies upon integrated 
infection control programs, antibiotic stewardship and 
may include the use of adjunctive probiotics. Clinical 
presentation of pediatric AAD and CDI are different 
than adult AAD and CDI symptoms. These differences 
should be taken into account when rating severity of 
disease and prescribing antibiotics.
Key words: Antibiotics; Antibiotic-associated diarrhea; 
Clostridum difficile  infections; Adults; Pediatrics; 
Diarrhea; Risk factors; Treatments; Prevention
© The Author(s) 2016. Published by Baishideng Publishing 
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Core tip: Differences and similarities in clinical pre-
sentation and response to treatments were noted in 
pediatric and adult patients with regards to antibiotic-
associated diarrhea and Clostridum difficile  infections. 
Pediatric patients typically become symptomatic more 
rapidly, but also recover quicker than adults. While 
antibiotics are the major risk factor for both children 
and adult patients, adults have a more complex risk 
factor profile. Children respond best to metronidazole, 
while adults respond better to vancomycin. More 
studies are needed to characterize the disease process 
in antibiotic-associated diarrhea and treatment 
guidelines for pediatric patients.
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INTRODUCTION
Clinical presentation and response to treatments often 
differ radically in pediatric compared to adult patient 
populations. Although antibiotic-associated diarrhea 
(AAD) and Clostridium difficile (C. difficile) infections 
(CDI) are widely studied in adult populations, a 
comparison of the disease processes in the pediatric 
population is not as well described, especially for C. 
difficile infections[1]. If pediatric and adult patients 
respond differently to therapies for these conditions, 
this may be an important clinical concern, as global 
guidelines are typically based on adult patients, not 
children[2,3]. Results from clinical trials performed in 
adults might be extrapolated to pediatric populations 
if the response is similar in these two populations. 
Currently, there are limited comprehensive com-
parisons of these two populations for AAD and CDI. 
The national prevalence of both pediatric[4-6] and 
adult cases of CDI[7,8] are increasing over time, but 
the secular trends for pediatric and adult rates of 
AAD have not been documented. The impact of AAD 
and CDI on healthcare systems is high. In the United 
States, 453000 cases of incident CDI occurred in 2013, 
associated with 29300 deaths and increased costs 
of healthcare from $3427-$9960/patient[9,10]. Many 
incident cases of adult CDI will recur (up to 136000/
year) and these cases are associated with higher 
costs ($11631/case)[10]. The burden and costs of 
pediatric AAD have not been documented by national 
surveillance studies. AAD is also associated with longer 
hospitalizations, higher healthcare costs, increased 
risks of mortality and acquiring other nosocomial 
infections[11]. The aim of this review is to update the 
literature and compare AAD and CDI in pediatric and 
adult populations and determine significant differences 
and similarities that might impact clinical decisions.
DEFINITIONS
Pediatric vs adult
Generally for AAD, the pediatric population is defined 
as aged one month to 18 years of age, but for pediatric 
CDI, the reported age range shifts to 1-21 years 
old[1,12-14]. For pediatric CDI, infants younger than one 
year old are typically excluded from being defined as 
CDI cases due to their high asymptomatic carrier rate 
associated with the lack of toxin A/B receptors in the 
immature colon and high prevalence of other etiologies 
of diarrhea (most commonly viral causes)[15]. Adults 
are usually defined as ≥ 21 years old, but published 
studies have included ages as young as 16 years old. 
The lower limit for pediatric AAD is difficult to define 
without knowing more about asymptomatic carriage 
of other etiologies of AAD. Although it is appreciated 
that the intestinal microbiome is in an active stage of 
change during early life, few studies report clinical data 
by finer age strata other than either pediatric or adult. 
For this review, we include all ages under 21 years 
as pediatric AAD and ages 1-21 years old as pediatric 
CDI.
Diarrhea
The World Health Organization defined diarrhea in 
adults and children as “the passage of three or more 
loose or liquid stools per day, or more frequently than 
is normal for the individual”[16]. In clinical studies, 
diarrhea in adults is usually defined as ≥ 3 liquid 
stools/d for at least two days[2,17]. Pediatric diarrhea is 
typically defined using the WHO definition[16], but one 
study defined pediatric diarrhea as ≥ 5 stools/d[18].
Antibiotic-associated diarrhea
AAD is defined as diarrhea associated with antibiotic 
exposure, either while on antibiotics or for up to eight 
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weeks after antibiotics have been discontinued[19,20] 
Although the etiologies for AAD are varied and not 
all the pathogens are identifiable, nearly one-third 
of AAD cases are due to C. difficile. In pediatric AAD, 
etiologies may include viruses (25% in one study)[21] 
or C. difficile (22%-30%), but also may be due directly 
to osmotic imbalances in the intestines brought about 
by antibiotic exposure and microbiota disruption. 
In adults with AAD, identifiable pathogens include 
C. difficile (13%-28%), C. perfringens (3%-21%), 
Staphylococcus aureus (1%-28%) and less commonly 
Klebsiella oxytoca[22-27].
C. difficile infections
CDI diagnosis is based on standard definitions in 
practice guidelines, which are based on a positive 
result in two factors: (1) presence of C. difficile in 
the stool [e.g., microbial culture, cytotoxin assay, 
enzyme immunoassay, nucleic acid amplication test, 
or polymerase chain ribotyping (PCR)]; and (2) 
the presence of gastrointestinal symptoms (e.g., 
diarrhea, colitis, etc.) without another etiology being 
present[2,28,29]. While there is no standard definition 
of severe CDI, most experts agree that severe CDI 
should include at least one of the following: elevated 
leukocyte counts, elevated creatinine, albumin 
counts, intensive care unit admission, surgery or 
pseudomembranous colitis[2].
Onset of symptoms
Laboratory testing and surveillance data allows both 
the setting (location of disease onset) and the time of 
onset (incubation time) to be determined. If an etiology 
can be determined (e.g., C. difficile), the source of 
the infection may be determined. AAD or CDI cases 
may begin exhibiting symptoms at healthcare settings 
(including hospitals and long-term care facilities) or 
in community settings (home, daycares, etc.), but 
the setting is typically only defined for CDI cases. The 
incubation time for AAD (defined as the time between 
antibiotic initiation and the onset of diarrhea) falls into 
two groups: early onset, occurring during antibiotics 
and delayed onset, which may occur from 2-8 wk 
after the antibiotics have been discontinued[30,31]. The 
incubation time for CDI should best be measured from 
the first day of the inciting antibiotic to the first day of 
diarrhea associated with a positive C. difficile assay, 
but most studies of CDI have not collected data related 
to the first day of antibiotic for all their patients. 
As a consequence, the incubation time for CDI is 
typically measured starting from either the first day of 
healthcare facility admission or first positive laboratory 
test for C. difficile and ending at the first day of defined 
diarrhea. Healthcare facility-associated (HCFA) cases 
are assumed to have acquired C. difficile either during 
their current stay or during a previous recent stay at a 
healthcare facility within the previous 12 wk. The onset 
of HCFA cases may be either during their current stay 
(healthcare-onset) or after discharge (community-
onset). Community-acquired CDI (CA-CDI) cases are 
defined as a symptom onset in the community with 
no associated healthcare facility exposure in the prior 
12 wk, or onset ≤ 48 h of a current hospital admission 
and the last discharge from a healthcare facility 
beyond 12 wk of the admission[2].
EPIDEMIOLOGY
Incidence and setting
Pediatric AAD incidence: National surveillance 
studies have not been done documenting the incidence 
of pediatric AAD in the general population, but 
estimated frequencies of pediatric AAD ranging from 
6-80/100 can be obtained from the control groups in 
randomized, placebo-controlled clinical trials or from 
prospective cohort studies, as shown in Table 1. From 
a meta-analysis of 22 clinical trials of children exposed 
to antibiotics, AAD in the controls ranged from 4.3% to 
80%, with a median incidence of 22%[19]. The incidence 
of pediatric AAD varies largely due to two main 
factors: the age of the child and the type of antibiotic 
to which the child is exposed. From birth to 6 mo, 
infants seem to be protected by maternal antibodies 
supplied in the breast-milk and by the establishment 
of normal microbiome during the passage through the 
birth canal[32,33]. Neonates who are not breast-fed or 
are delivered by Caesarian section do not benefit from 
these two protective mechanisms[33]. As infants are 
transitioned to solid food, the incidence of AAD seems 
to increase, perhaps reflecting a shift in the normal 
intestinal microbiome. Few studies have documented 
the incidence of pediatric AAD in the healthcare 
setting, but the frequency in outpatients has been 
reported ranging from 6%-75%, as shown in Table 1. 
The reported mean age of pediatric AAD ranges from 
18-48 mo. old (Table 1). Few studies of pediatric AAD 
have provided age, gender or racial distribution of their 
cases, but one study reported no significant differences 
by gender[34].
Adult AAD incidence: The incidence of adult AAD 
cases ranges from 7-33/100 in adult inpatients to as 
few as 2.5/100000 person-years for adult outpatients 
or mixed inpatient and outpatient cases receiving 
antibiotics, as shown in Table 1. One review of six 
randomized trials found the frequency of AAD in elderly 
patients (≥ 65 years old) ranged from 10%-37% in 
control groups[35]. While few studies of adult AAD have 
provided age or gender data, two studies reported 
the mean age was 49-72 years old and 47% were 
female[36,37]. Few studies of AAD report distribution by 
race or ethnicity.
McFarland LV et al . Pediatric vs  adult AAD and CDI
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pediatric Clostridium difficile  infections vs  adult Clostridium difficile  infections
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Characteristics Pediatric AAD 
rate/100 
(n/total)
Ref. Adult AAD 
rate/100 unless 
noted (n/total)
Ref. Pediatric CDI 
rate/10000 
(n/total)
Ref. Adult CDI 
rate/10000 
(n/total)
Ref.
Incidence: 29 (42/144)1 Shan[93] 7 (14/204)1 Duman[158] 22 Sathyendan[38] 4.3 pd3 Stevens[173]
 Inpatient 80 (8/10)1 Jirapinyo[151] 9 (10/112)1 Selinger[112]  5.8 ad3 Chen[167] 5.4 py4 Vesteinsdottir[73]
9.6 (67/743)2 Elseviers[37]  6.5 pd4 Kim[168]  5.7 hd2 Wenisch[102]
10.4 (153/1471)1 Allen[159]  6.8 v3 Benson[70]  10 pd2 Hsu[103]
13 (13/98)1 Pozzoni[160] 12.8 ad4 Zilberberg[5]  12 py5 Kuntz[174]
15 (14/96)1 McFarland[96]  13.4 pd5 de Blank[69]  29.2 pd2 McFarland[121]
19 (48/257)1 Li[161]  31.5 d4 Deshpande[169]  72 ad5 Zilberberg[7]
22 (14/64)1 Surawicz[162] 135.0 ad3 Duleba[18] 1282 Huang[65]
23 (55/242)2 Lusk[36] 416.71 Shan[93]  131 ad6 Jarvis[175]
25 (41/167)1 Ouwehand[163] 1000 (93/30)1 Dietrich[23]
29 (42/144)1 Shan[93] 2080 (83/399)2 McFarland[45]
33 (10/30)1 Dietrich[23]
 Outpatient 6.2 (14/225)2 Damrongmanne[76] 7.7/100000 py5 Hirschhorn[164] 143 Benson[70] 1.15 Fellmeth[75]
11 (71/650)2 Turck[63] 12/100000 py2 Levy[165] 200 (1/58)1 Arvola[21] 1.22 Levy[165]
16 (9/58)1 Arvola[21] 15/1005 Yapar[80] 390 (12/306)1 Boenning[170] 11.1 py5 Kuntz[174]
24 (8/33)1 Ahmad[152] 780 (9/115)1 Hyams[171]
26 (25/95)1 Vanderhoof[34] 790 (6/76)2 Mitchell[85]
29 (22/76)2 Mitchell[85]
52 (13/25)1 Saneeyan[153]
59 (16/27)1 Seki[154]
62 (31/50)1 La Rosa[155]
75 (27/36)1 Fox[156]
Mixed in- and 
out-patients
17 (20/120)1 Ruszczyński[78] 2.5/100000 v2 Meropol[166] 1.45 Khanna[40] 2.5 py5 Khanna[17]
23 (29/127)1 Kotowska[157] 2.14 Wendt[4] 5.42 Vesteinsdottir[73]
60 (1/161)1 Destura[172]
600 (7/120)1 Ruszczyński[78]
800 (10/127)1 Kotowska[157]
Setting NR NR 25% Khanna[40] 21% Garg[178]
Health-
care facility 
associated 
(HCFA) (% 
cases)
46% Crews[12] 53% Leung[179]
48% Sammons[44] 59% Khanna[17]
65% Pai[71] 68% Zilberberg[7]
69% Sandora[66] 89% McFarland[45]
71% Tschudin-
Sutter[72]
92% Kazadova[180]
74% Schwartz[176]
Community-
acquired (CA) 
(% cases)
NR NR 19% Tschudin-
Sutter[72]
  8% Kazadova[180]
25% Sandora[66] 11% McFarland[121]
26% Schwartz[176] 23% Zilberberg[7]
29% Pai[71] 27% Vesteinsdottir[73]
30% Samady[68] 33% Garg[178]
39% Kociolek[177] 34% Kutty[87]
41% Crews[12] 41% Khanna[17]
52% Duleba[18] 43% Leung[179]
54% Sammons[44]
67% Benson[70]
71% Wendt[4]
75% Khanna[40]
96% Søes[43]
Long term 
care facility 
acquired
NR NR NR -- 46% Garg[178]
Age 18 (4-31) mo Shan[93] 49 yr Lusk[36] 1.5 yr Shan[93] 59 yr Stevens[173]
mean (range) 25 ± 9 mo Mitchell[85] 72 yr Elseviers[37] 2 yr Khanna[40] 61 yr El Feghaly[182]
48 mo Vanderhoof[34] 2 yr Chen[167] 62 yr Huang[65]
2 yr Duleba[18] 64 yr Muto[59]
3 yr Pai[71] 64 yr Kim[98]
3 yr Hart[54] 65 yr Vesteinsdottir[73]
McFarland LV et al . Pediatric vs  adult AAD and CDI
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3-6 yr Kociolek[177] 66 yr McFarland[121]
4 yr Kim[115] 68 yr Khanna[17]
5.4 yr Morinville[100] 70 yr McFarland[64]
6 yr Sammons[44] 71 yr Garg[178]
6.5 yr Schwartz[176] 74 yr Wenisch[102]
6.5 yr Wendt[4] 74 yr Tabak[117]
6.7 yr Na[13] 75 yr Loo[57]
7 yr Crews[12] 77 yr Eyre[118]
8 yr Nylund[181]
9 yr Nylund[14]
10 yr Deshpande[169]
Gender 56% Vanderhoof[34] 46% Elseviers[37] 39% Crews[12] 47% Kim[98]
(% female) 48% Lusk[36] 41% Kociolek[177] 47% Loo[57]
42% Schwartz[176] 47% El Feghaly[182]
46% Hart[54] 49% Carignan[183]
46% Khanna[40] 49% Muto[59]
46% Kim[115] 49% Stevens[173]
46% Morinville[100] 53% Tabak[117]
47% Chen[167] 58% Eyre[118]
47% Wendt[4] 63% Garg[178]
47% de Blank[69] 64% Huang[65]
48% Nylund[14] 64% Wenisch[102]
48% Søes[43] 64% Vesteinsdottir[73]
49% Sammons[44] 66% Fellmeth[75]
49% Duleba[18] 66% Crabtree[184]
49% Pai[71] 67% Khanna[17]
49% Na[13]
Race: NR NR 59% Sathyendan[38] NR
Caucasian 65% Sammons[44]
Outbreaks n = 18 Kim[41] NR n = 6 Cartwright[48] n = 6 See[185]
(number of 
cases)
n = 6 Ferroni[47] n = 15 Lam[61]
n = 13 Kim[41] n = 21 Gaynes[55]
n = 98-174 Johnson[56]
n = 253 Muto[59]
n = 293 Pépin[58]
n = 1269 Jump[60]
n = 1703 Loo[57]
Ribotype NR NR 0% von Müller[51] 6.60% Wenisch[102]
NAP1/027/BI 
prevalence
0% Stoesser[52] 18% Scardina[186]
0% Sathyendan[38] 28% See[107]
< 1% Kociolek[177] 31% Miller[62]
< 1% Søes[43] 31% von Müller[51]
11% Schwartz[176] 50% Toltzis[50]
11% Kim[98]
19% Toltzis[50]
20% Duleba[18]
Pediatric CDI incidence: Incidence of pediatric 
CDI is dependent upon two main factors: age 
and hospitalization status. The high prevalence of 
asymptomatic carriers of C. difficile in neonates 
requires that the diagnosis of pediatric CDI be based 
on laboratory findings, the presence of intestinal 
symptoms, and the age of the child. Up to 67% of 
neonates delivered in hospitals may be colonized with 
C. difficile, but rarely show diarrheal symptoms. This 
is thought to be due to the lack of C. difficile toxin 
receptors in the neonatal colon, or from the presence 
of maternal anti-C. difficile toxin A/B antibodies 
in breast milk[1]. The high incidence of C. difficile 
acquisition by neonates may be due to exposures to C. 
difficile spores in the hospital environment[15]. However, 
in one study at two hospitals in New Zealand, only 3% 
of the neonates were asymptomatic carriers[38]. The 
incidence of pediatric asymptomatic colonization with 
C. difficile decreases with the increase in age from 6 
mo-1 year. In contrast, to the very low incidence of 
symptomatic CDI in neonates, symptomatic disease 
peaks 4-5 years of age, with the median age typically 
reported ranging from 1.5-10 years old (Table 1). This 
peak may reflect increased exposure to C. difficile 
1Data from control group of randomized control trial; 2Data from prospective cohort study of hospital or community population; 3Data from retrospective 
review of limited number of hospitals; 4Data from population-based surveillance; 5Data from retrospective review of national database or several hospitals 
or population-based ; 6Data from national point-prevalence survey. References are given by last name of first author and citation number in brackets. ad: 
Admissions; AAD: Antibiotic-associated diarrhea; CDI: Clostridium difficile infection; d: Discharges; hd: Hospital-days; NR: Not reported; pd: Patient-days; 
pop: Population; py: Person-years; v: Visits.
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spores found in soil or from other children with CDI 
in daycares or kindergardens[39]. After peaking at age 
4-5 years, the incidence of pediatric CDI declines from 
ages 6-18 years old to rates typically seen in adult CDI 
cases. Rates of CDI may also range widely depending 
upon type of healthcare facility exposure: rates range 
from 2-420/10000 d for pediatric inpatients, while 
ranging from 14-800/10000 for outpatient children. 
The wide range of CDI rates shown in Table 1 may 
reflect differences in data collection methods rather 
than a true difference in incidence. Inpatient data 
may be more accurate, as it is usually collected from 
prospective cohort studies or surveillance programs. 
The higher rates reported in outpatient studies are 
often collected from control groups from randomized 
trials and may not accurately reflect true population 
rates. Data from the United States Healthcare Cost 
and Utilization Project Kids’ Inpatient Database found 
rate of pediatric CDI of 12.8/10000 in inpatients, 
with peak ages of 1-4 years old[5]. A CDC Emerging 
Infections surveillance program across ten United 
States states from 2010-2011 found 71% of pediatric 
CDI was from outpatients, the peak age was < 1 year 
old (71/100000), and children 2-3 years old had the 
next highest incidence (34/100000)[4]. Secular trends 
of increasing incidence for pediatric CDI over time 
have been noted. A doubling of pediatric CDI cases 
was noted in two national surveys from 1997-2006[5,14] 
and another study found a 12-fold increase in pediatric 
CDI from 1991-2009[40]. From a meta-analysis of six 
clinical trials of children exposed to antibiotics, CDI in 
the controls ranged from 0% to 8%, with a median 
of 4%[19]. Most pediatric CDI is acquired in healthcare 
facilities, but more CA-CDI cases are being reported. 
Pediatric CA-CDI ranges from 19%-96%, with a 
median of 41% (Table 1). Healthcare facility acquisition 
of pediatric CDI ranges from 25%-74%, with a median 
of 65% (Table 1). Community sources for pediatric 
CDI cases may include daycare centers, where CDI 
outbreaks have been reported[41] or transmission from 
recently hospitalized family members[39,42]. From a 
cohort of Danish children attending a general practice 
for intestinal complaints, 96% of the CDI cases were 
CA, with 69% also having another pathologic agent 
(viruses or E. coli) and the most common ribotype 
of C. difficile was type 014 (35%), while only < 1% 
had NAP1 ribotype[43]. Gender seems not to play an 
important role in pediatric CDI, as the distribution 
between female and male cases is nearly equivalent 
(Table 1). From 16 studies of pediatric CDI, the 
range of frequencies for females was 39%-49%. 
Few studies report race or ethnicity, but two studies 
found most (59%-65%) of pediatric CDI cases were 
Caucasian[38,44].
Adult CDI incidence: From national surveillance 
studies of CDI, the incidence of adult CDI has ranged 
from 1-11/10000 for outpatients to 4.3-131/10000 
for adult inpatients (Table 1). Estimates of incidence 
extrapolated from a clinical trial and a cohort of adults 
on one hospital ward resulted in higher rates (1000
-2080/10000)[23,45]. Even excluding the two highest 
estimates, rates of adult CDI are typically higher for 
adult inpatients compared to outpatient populations. 
In adult CDI cases, most (21%-92%) cases are 
reported as HCFA-CDI (Table 1), while only 8%-43% 
have been CA-CDI. Secular trends in adult CDI cases 
increased by four-fold from 1998-2006[11] and United 
States national surveillance data show continued 
increases in the rates of adult CDI from 2000-2013[7,8]. 
Elderly patients in long-term care facilities are also 
experiencing increasing CDI rates[46]. The reported 
median age of adult CDI ranges from 59-77 years old 
(Table 1). Most cases (47%-67%) of adult CDI are 
female, while ethnicity or race data is rarely reported 
in studies of adult CDI.
Outbreaks
Pediatric AAD outbreaks: Few outbreaks of pediatric 
AAD have been reported in children < 2 years old. 
Of 65 children in daycares who were followed for 
3.5 mo., five outbreaks of diarrhea occurred (n = 21 
developed diarrhea), and while most (62%) were due 
to C. difficile, eight (38%) had no known etiology[41]. 
There are few other reports of pediatric AAD outbreaks 
excluding those with CDI.
Adult AAD outbreaks: The difficulty of determining 
outbreaks of AAD is that early reports in the literature 
of outbreaks may have been due to C. difficile, but 
were missed as testing was not standard before 1980’
s. In addition, the lack of assays for other etiologies 
of AAD has limited documentation of AAD outbreaks. 
One study of adult inpatients with diarrhea, 591/4659 
(13%) of AAD cases were due to C. difficile, 155 (3%) 
due to Clostridum perfringens and 10 (0.2%) due to 
Staphylococcus aureus. No clustering of C. perfingens 
or S. aureus DNA fingerprints was found to indicate an 
outbreak situation[22].
Pediatric CDI outbreaks: A few, small CDI outbreaks 
involving 6-13 children have been reported[41,47,48]. 
Despite a high rate of C. difficile carriage in several 
pediatric patient studies[39,49], large CDI outbreaks were 
found to be uncommon. An epidemiological study at a 
Belgian pediatric hospital found asymptomatic carriage 
of C. difficile was common (76/114, 67% were 
positive for C. difficile) but only 13 children developed 
CDI and 2 developed necrotizing entercolitis, and no 
evidence of CDI outbreaks were observed. Clustering 
of serogroups B and C were observed, but most were 
asymptomatic carriers[49].
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A hypervirulent strain of C. difficile (NAP1/027/BI) 
is responsible for outbreaks in adults, but is detected 
only rarely in pediatric CDI populations[50], and not 
found by others[38,51-53], making its contribution to 
disease in children less certain than in adults. In 
a study, of 28 isolates of C. difficile isolated from 
children, eight different genotypes were seen, but none 
were 027 ribotype[52]. While in most studies of pediatric 
CDI, < 20% of isolates are the hypervirulent strain 
(Table 1), a few studies found higher frequencies of 
this ribotype. NAP1/027/BI isolates were found in 19% 
of 195 samples from children hospital isolates (median 
age of 2.5 years old)[50] and in 20% of pediatric cases 
in Poland[18]. Most studies find ribotype 014 is the most 
common strain isolated from pediatric CDI cases. Two 
studies in New Zealand and Australia reported ribotype 
014 was the most commonly isolated (37% and 48%, 
respectively)[38,54] and also from a study in Germany 
(26%)[55].
Adult CDI outbreaks: The notoriety of CDI is due 
to its ability to cause large outbreaks of disease in 
adults at healthcare facilities that are difficult to control 
without a multidisciplinary infection control programs. 
Nosocomial outbreaks have been reported in adult 
inpatients since the 1980s, with as few as 15 cases 
to as many as 1703 (Table 1)[55-58]. Large outbreaks 
of CDI occurred in 12 Canadian hospitals in Quebec 
providence during 2004 (n = 1703 CDI cases) which 
were associated with high mortality and the increased 
incidence was associated with the emergence of a 
hypervirulent strain of C. difficile typed as NAP1/027/
BI[57]. A large outbreak of CDI with 253 adult 
nosocomial cases was reported at a teaching hospital 
following increased fluoroquinolone use[59]. Jump 
et al[60] reported outbreaks of CDI in five hospitals 
during 2006 in Ohio, totally 1269 cases and 66% of 
the isolates were typed as NAP1/027/BI. However, 
other strain types of C. difficile are also responsible 
for outbreaks. During one outbreak at a Hong Kong 
rehabilitation ward, 80% of 15 cases of adult CDI at 
were due to ribotype 02[61]. NAP1/027/BI C. difficile 
strains continue to be responsible for outbreaks of CDI 
in adult patients, particularly elderly patients in Canada 
and this serotype is now frequently isolated in adults 
globally (Table 1)[57,62]. 
Risk factors
Pediatric AAD risk factors: Risk factors for AAD may 
broadly be divided into two modalities: host factors 
(e.g. age) and disruptive factors (e.g. antibiotics) 
that may disturb the normally protective intestinal 
microbiome[1,20]. The two main risk factors for pediatric 
AAD are age (1-2 years old) and type of antibiotic 
exposure, as shown in Table 2. In one study of 650 
outpatient children on oral antibiotics, symptomatic 
pediatric AAD occurred in 18% of outpatient children 
aged 1-2 years old and in 3% for older children 
(3-16 years)[63]. The incidence of AAD may be even 
higher (60% to 70%) if broad-spectrum antibiotics 
(cephalosporins, penicillins, etc.) were used. The 
number of controlled studies determining risk factors 
for pediatric AAD is limited. Few other risk factors for 
pediatric AAD have been established.
Adult AAD risk factors: Most studies determining 
risk factors for AAD have focused on the most 
common etiology of AAD, namely C. difficile. Literature 
is limited for risk factors of non-C. difficile AAD cases. 
One study prospectively followed 4659 adult inpatients 
for AAD and found 13% were due to C. difficile, 3% 
were due to Clost. perfringens and 0.2% were due 
to S. aureus[22]. Risk factors for adult C. perfringens-
associated AAD included: age > 80 years (OR = 13.7), 
female gender (OR = 2.0) and antacid use (OR = 
2.8)[22]. Another study of adult patients with AAD found 
age > 80 years, previous antibiotic use (OR = 2.3) and 
proton-pump inhibitor (PPI) use (OR = 2.0) increased 
the risk of AAD, but co-morbidities or surgery had no 
effect on the risk of AAD[37].
Pediatric CDI risk factors: In contrast to AAD, there 
are numerous studies for CDI risk factors (Table 2). 
Risk factors for CDI involve a triad of factors: (1) host 
factors (e.g., age, gender, co-morbidities); (2) factors 
disruptive of the protective intestinal microbiome 
(e.g., antibiotics, surgery, other medications, 
nasogastric tube feeding, gastrostomy); and (3) 
increased exposure to C. difficile spores (e.g., longer 
healthcare facility stays, prior admissions, infected 
room-mates)[64,65]. However, not all factors act equally 
in the pediatric vs adult populations. The risk factors 
that are common for pediatric CDI include: age 1-4 
years old, co-morbidities (especially cancer and 
inflammatory bowel disease), exposure to antibiotics 
within the prior 12 wk (particularly multiple antibiotics, 
cephalosporins, and penicillins), and prior or current 
hospitalization (Table 2)[38,66-69]. Conversely, risk factors 
for pediatric CA-CDI are not as strongly associated 
with antibiotic exposure[70]. From the CDC Emerging 
Infections Program, data from 10 United States states 
from 2010-2011 found 71% of the 944 of pediatric 
CDI cases were CA-CDI and of these, 67% had no 
antibiotic exposure in the two weeks prior to CA-CDI 
diagnosis[4]. The five studies that show the highest 
rate of no prior antibiotic exposures (19%-67%) were 
largely CA-CDI pediatric cases (Table 2)[4,12,40,70,71]. In a 
study of 202 children with CDI, CA cases were found 
to have less co-morbidities (74% vs 98%) and less 
antibiotic exposure (42% vs 77%) than HCFA cases, 
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Host Factors Pediatric AAD Ref. Adult AAD Ref. Pediatric CDI Ref. Adult CDI Ref.
Age < 2 yr (RR = 
1.8)
Turck[63] > 70 yr Elseviers[37] 1-4 yr Tai[67] > 65 yr Hu[189]
> 70 yr Asha[22] 6 mo-2 yr McFarland[1] >  65 yr Beaulieu[190]
> 65 yr Vardakas[74]
> 65 yr Pepin[106]
> 65 yr McFarland[89]
> 85 yr Vesteinsdottir[73]
Yes (RR = 1.2) Eyre[118]
Yes (HR = 1.4) Marwick[191]
Comorbidity NR No Elseviers[37] Yes (OR = 1.1) Sammons[44] Yes (OR = 1.3) McFarland[121]
Yes (OR = 1.1) Tai[67] Yes (OR = 4) Wenisch[102]
Yes (OR = 2.0) Samady[68] No Tabak[117]
No Vesteinsdottir[73]
Chemotherapy NR No Elseviers[37] Yes (HR = 1.9) de Blank[69] Yes (OR =2.3) Dubberke[192]
 or cancer Yes (OR = 3.8) Tai[67] Yes (OR = 3.6) Huang[65]
Yes (RR = 2.7) Sathyendan[38]
IBD NR No Elseviers[37] Yes (OR = 11.4) Hourigan[187] Yes (OR = 3.3) Hourigan[187]
Yes (OR = 11.4) Nyland[14] No Leung[179]
Yes (OR = 4.5) Kelsen[188]
Prior GI 
condition
NR NR NR Yes (OR = 2.8) McFarland[121]
Immuno-
deficiency
NR NR Yes (OR = 6.0) Samady[68] NR
Yes (OR = 8.1) Sandora[66]
Disruptive factors
Previous 
antibiotics
NR OR = 2.3 Elseviers[37] Yes (OR = 1.2) Sathyendan[38] Yes (OR = 1.3) Loo[57]
Yes (OR = 2.2) Sandora[66] Yes (HR = 1.4) Stevens[173]
Yes (RR = 2.1) McFarland[121]
Yes (RR = 2.8) Samady[68] Yes (HR = 3.4) Marwick[191]
Yes (OR = 3.6) Huang[65]
Type of 
antibiotic
Amoxicillin/
clavulanate 
(RR = 2.4)
Turck[63] Amino (HR = 
1.3) and Ceph 
(HR = 2.4)
de Blank[69] Clind (OR = 4.3)
Ceph (RR = 3.8)
Johnson[56]
Asha[22]
Quino Sandora[66] Diclox, Clind, Vesteinsdottir[73]
(OR = 17.0)  Ceftriaxone
 (OR = 2.2-7.5)
Ceph and Pen McFarland[64]
 (OR = 2.1)
Clind, Quino, Loo[57]
 Ceph (OR = 3.8)
Clind/Levo/
Ceftrizone (OR = 3.0)
Muto[59]
Cefoxitin (OR = 2.7) Carignan[183]
Ceph (OR = 5.6) Dubberke[192]
Quino  (HR = 3.4) Pépin[58]
No prior 
antibiotics < 2-8 
wk prior
NR NR 2% Sammons[44]   6% McFarland[64]
5% Duleba[18] 13% Khanna[17]
8% Samady[68] 20% McFarland[121]
13% Chen[167] 40% Loo[57]
19% Crews[12] 96% (CO) Fellmeth[75]
22% Khanna[40]
27% Pai[71]
43% (CO) Benson[70]
67% (CO) Wendt[4]
Abdominal 
surgery
NR NR Yes (OR = 3.3) Sandora[66] Yes (OR = 2.6) Huang[65]
Yes (OR = 2.8) Zerey[193]
PPI NR OR = 2.0 Elseviers[37] Yes (HR = 1.4) de Blank[69] Yes (OR = 1.6) Dubberke[192]
OR = 2.8 Asha[22] Yes (RR= 1.7) Sathyendan[38] Yes (OR = 1.8) Muto[59]
Yes (RR = 2.4) Nylund[181] Yes (OR = 2.8) Stevens[173]
Yes (OR = 4.2) Samady[68] Yes (OR = 6.1) Peled[25]
No Brown[194] No Khanna[17]
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No Sandora[66] No Leung[179]
No Sammons[44] No Vesteinsdottir[73]
No Pépin[58]
No Marwick[191]
No Huang[65]
Histamine-2 
receptor 
antagonist
NR NR Yes (RR = 2.2) Brown[194] Yes (OR = 3.1) Peled[25]
Exposure to C. difficile spores
Prior 
hospitalization
NR NR Yes (OR = 1.7) Tai[67] Yes (OR = 1.3) McFarland[121]
Yes Samady[68] Yes (OR = 2.0) Eyre[118]
(OR = 2.3) Yes (RR = 2.3) Vesteinsdottir[73]
No Sandora[66] Yes (HR = 4.7) Marwick[191]
Yes (RR = 5.1) McFarland[64]
No Huang[65]
Prior long term 
care residence
NR NR NR Yes (OR = 3.9) Vesteinsdottir[73]
Yes (HR = 4.1) Marwick[191]
Prolonged length 
of stay (current)
NR NR Yes (OR = 15) Tai[67] Yes (RR = 1.01) Asha[22]
Yes (OR = 2.8) Huang[65]
Yes (OR = 5.1) Lee[195]
No Carignan[183]
Infected 
roommates/CD 
proximity/CD 
pressure
NR NR NR Yes (RR = 1.7) McFarland[45]
Yes (OR = 4.0) Dubberke[192]
Previous CDI NR NR NR Yes (HR = 4.5) Stevens[173]
No Khanna[17]
which had a higher rate of CDI recurrences (21% 
vs 9%, respectively)[72]. Conflicting findings on co-
morbidity was reported in another study, which found 
more gastrointestinal co-morbidities (23%) in CA-
CDI compared to HCFA-CDI cases (6%)[71]. In two 
studies, CA-CDI pediatric patients were younger than 
HCFA cases[40,71], but had similar rates of no antibiotic 
exposure and recurrence rates. The literature presents 
different results for proton-pump inhibitors, some 
showing significant risk, while others do not (Table 2). 
Further research may help to define the role of proton-
pump inhibitors and pediatric CDI. 
Adult CDI risk factors: The risk factors that are 
common for adult CDI also include the same triad of 
factors (Table 2): host factors (age, co-morbidities), 
disruptive factors (exposure to antibiotics or other 
medications) and increased exposure to C. difficile 
spores (prolonged lengths of stay at healthcare 
facilities). A broader range of antibiotics have been 
identified as high-risk in adults, but there are not as 
many studies done in children (Table 2). However, 
many additional types of risk factors were identified 
in several studies using multivariate models to adjust 
for other simultaneous risk factors. These included 
enemas (aRR = 3.3), gastrointestinal stimulants 
(aRR = 3.1), stool softeners (aRR = 1.7)[64], cytoxic 
drugs (aRR = 8.1), feeding tubes (aRR = 2.8)[22], 
albumin level < 2.7 mg/dL (aOR = 3.8), leukocytosis 
[WBC count > 13000 cells/mL (aOR = 2.7), impaired 
functional capacity (independent was baseline vs 
required assistance or bedridden, aOR = 9.14), watery 
diarrhea (aOR = 17.4)[25], and mechanical ventilation 
(aOR = 1.9)[73]. A meta-analysis pooled data from five 
studies of adult CDI and found the same risk factors 
associated with BI/NAP1/027 strain as with other 
strain ribotypes: age > 65 years (aOR = 1.77, 95%CI: 
1.31-2.4) and fluoroquinolone use (aOR = 1.96, 
95%CI: 1.37-2.80)[74]. The one study with the highest 
report of no antibiotic exposure (96%) was also mostly 
community cases[75]. Exposure to infected room-mates 
or proximity pressure has been reported by several 
studies in adult CDI (Table 2), but not in children, 
which may be due to the lack of HCFA outbreaks 
reported in pediatric hospitals. The literature presents 
different results for proton-pump inhibitors, some 
showing significant risk, while others do not (Table 2).
Comparison of epidemiology of pediatric and 
adult AAD: The overall median incidence of pediatric 
AAD averages 27/100 compared to 15/100 for adult 
AAD, but the range in both populations is wide (< 
1%-80%), as shown in Table 1. The incidence from 
these studies may be confounded by method the 
References are given by last name of first author and citation number in brackets. AAD: Antibiotic-associated diarrhea; amino: Aminoglycoside; CDI: 
Clostridium difficile infections; IBD: Inflammatory bowel disease; ceph: Cephalosporins; clind: Clindamycin; CO: Community-onset; diclox: Dicloxacillin; 
HR: Hazard ratio; levo: Levofloxacin; NR: Not reported; OR: Odds ratio; pen: Penicillin; PPI: Proton-pump inhibitor; RR: Relative risk; quino: Quinolones.
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data was collected and from differences in the age 
distributions, the types of antibiotic exposures and 
whether the antibiotic exposure occurred while the 
patient is hospitalized or as an outpatient. Data for 
secular trends of pediatric AAD and adult AAD have 
not been documented, so it is uncertain if non-C. 
difficile related AAD is increasing or decreasing over 
time. Limited data is available on non-C. difficile 
etiologies of AAD and, without having a pathologic 
etiology to link time of occurrence and place, it is 
impossible to establish the existence of non-C. difficile 
outbreaks of AAD for both pediatric and adult cases of 
AAD. It is difficult to compare risk factors for pediatric 
vs adult AAD due to the lack of studies for AAD risk 
factors.
Comparison of epidemiology of pediatric and 
adult CDI: While the overall median incidence from 
Table 1 of pediatric CDI (31/10000) may be higher 
than adult CDI (10/10000), these rates are highly 
influenced by method in which the data was collected, 
differences in age distribution, setting (inpatient or 
outpatient) and underlying risk factor distribution. 
National, prospective surveillance studies of CDI 
rates have only recently become established. The 
prevalence of CDI is not constant over all age ranges; 
pediatric CDI peaks at age 5, while adult CDI peaks 
at age 67. The increase in pediatric CDI in early 
childhood may be due to an increase in antibiotic use, 
especially associated with respiratory infections and 
perhaps to exposure to other children in schools and 
daycare settings. Adult cases of CDI may increase 
with age due to the development of more chronic 
co-morbidities, higher rates of hospitalizations and 
increased exposure to antibiotics with age. Generally, 
more CA cases are reported for pediatric CDI (41%) 
compared to adult cases of CA-CDI (30%). The 
rate of CA-CDI is increasing, especially in children. 
Significantly more adult CDI cases are female (median 
of 56%) compared to female pediatric cases (median 
of 47%, P < 0.01). There have been few studies that 
have reported outbreaks of pediatric cases of CDI, 
while large outbreaks of CDI in adult inpatients are 
commonly reported. One difference between adult and 
pediatric CDI populations is the higher prevalence of 
the hypervirulent epidemic C. difficile strain NAP1/027/
BI in adult patients. This may be due to the restriction 
of fluoroquinolone use in children, as this antibiotic 
is a risk factor for NAP1/027/BI CDI in adults. Some 
risk factors are similar for pediatric and adult CDI: age 
and exposure to antibiotics. In contrast, while prior 
hospitalization is an established risk factor for adult 
CDI, its role in pediatric CDI is unclear, especially as 
pediatric CA-CDI rates continue to increase. Adults 
with CDI have a more complex risk factor profile than 
pediatric CDI.
CLINICAL PRESENTATION
Incubation time
Pediatric AAD incubation time: The mean 
incubation times for pediatric AAD is from 2-6 d, 
with AAD typically occurring while the children are 
on antibiotics (85%-92% of cases); only 8%-15% 
report delayed-onset AAD post-antibiotics (Table 
3). For example, in 225 outpatient children given 
antibiotics, the mean onset was 2.3 ± 1.1 d and all 
cases of AAD occurred while the children were taking 
the antibiotics[76]. The time of onset is similar for 
outpatients (2-5 d)[63,76] and for inpatients (4-6 d)[77,78].
Adult AAD incubation time: The mean incubation 
time for adult AAD cases is 3-18 d, but the time of 
onset (while on antibiotics vs delayed-onset) was not 
as consistently reported as in studies of pediatric AAD. 
Studies with lower rates of delayed-onset AAD tend to 
suffer from an insufficient follow-up after antibiotics 
were discontinued[79,80]. In one controlled trial of 
adults on antibiotics randomized to a probiotic drink or 
control group, only 5 (26%) of the 62 control patients 
developed AAD while on antibiotics, while most (74%) 
had delayed-onset AAD[81].
The incubation period of AAD is related to time 
of normal flora recovery after antibiotic exposure. In 
one study of six healthy adult volunteers exposed to 
oral amoxicillin (1.5 g/d for 5 d), a major shift in the 
normal flora was detected within 24 h after antibiotic 
exposure; 88% of the normal flora recovered within 
30 d and only 89% recovered after 60 d[82]. One 
case of an adult patient with amoxillcin-clavulanic 
acid treatment was followed for changes in normal 
flora[83]. After day four of antibiotic exposure, there 
was a complete absence of Clostridium cluster XIVa 
(down from 20% from day 0) and the presence 
of Faecalibacterium decreased from 33% to 15%. 
These two taxa are the main ones associated with the 
production of butyrate (the preferred energy source 
of colonocytes). The intestinal microflora of three 
healthy adult human volunteers was characterized 
using 16S rRNA sequencing before and after exposure 
to ciprofloxacin (500 mg bid for 5 d). Ciprofloxacin 
impacted 33% of the bacterial taxa in gut, reducing 
both diversity and taxonomic richness. Taxonomic 
composition mostly recovered within 4 wk post-
antibiotic exposure, but several taxa failed to recover 
within 6 mo. Ciprofloxacin was found to reduce 30% of 
the taxa in these individuals[84].
Pediatric CDI incubation time: The mean incubation 
period for pediatric CDI is 3-10 d, as shown in Table 
3[71,85].
Adult CDI incubation time: The mean onset of the 
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Ped AAD Ref. Adult AAD Ref. Ped CDI Ref. Adult CDI Ref.
Incubation period
(mean days after 
antibiotic start or C. 
difficile positive)
2. 3 ± 1.1 d Damrongmanee[76] 3.2 ± 2 d Dietrich[23] 3 d Mitchell[85] 2 d McFarland[45]
2.4 (1-8) d Mitchell[85] 3.7 ± 2.6 d Duman[158] 10 d Pai[71] 6 d Chang[86]
4.0 ± 4.3 d Corrêa[77] 7 d Hickson[81] 10 d James[197]
4.9 ± 2.5 d Shan[93] 8 d (1-30 d) Lusk[36] 12 d Figueroa[90]
4.9 ± 3 d Kotowska[157] 9 ± 1 d Yapar[80] 13 d Wenisch[102]
5.3 ± 3.5 d Turck[63] 16 d (6-60 d) Pozzoni[160]
6.2 ± 4.2 d Ruszczyński[78] 18 d McFarland[96]
Time of Onset
(while on antibiotics 
vs delayed-onset post-
antibiotic)
85% vs 15% Turck[63] 26% vs 74% Hickson[81] 80% vs 
20%
Duleba[18] 23% vs 77% Chang[86]
92% vs 8% Corrêa[77] 27% vs 73% McFarland[96]
38% vs 62% Pozzoni[160]
71% vs 29% Can[79]
75% vs 25% Duman[158]
85% vs 15% Yapar[80]
Severity of disease
Duration 2.6 ± 1.1 d Damrongmanee[76] 1-6 d Allen[159] 2 d Denno[97] 5.4 ± 1.8 d Ouwehand[163]
(mean ± std. dev.) or 
median (range) days
3.9 ± 2.3 d Destura[172] 2-25 d McFarland[96] 2-9 d McFarland[1] 6.6 d Wenisch[102]
4 ± 3 d Turck[63] 3 (2-5) d Pozzoni[160] 6 d Crews[12] 13 ± 13 d McFarland[89]
4.1 ± 2.1 d Ruszczyński[78] 4.4 ± 2.5 d Dietrich[23] 7-8 d Duleba[18]  13 ± 7.4 d Morrow[198]
5 ± 2.8 d Corrêa[77] 4.9 ± 2 d de Souza[139] 26 ± 56 d Hsu[103]
9 ± 1 d Shan[93] 5.4 ± 1.8 d Ouwehand[163]
21.5 (1-72) d Lusk[36]
Asymptomatic 
carriers
NR NR 26% Sandora[66]      6% Jarvis[175]
35% Enoch[196]   9.4% Bruns[199]
45% Rousseau[53]   9.7% Leekha[200]
67% Delmée[49]    61% McFarland[45]
Mild-moderate 
diarrhea 
Most common Most common 23% Pai[71]    35% McFarland[201]
66% Schwartz[176]    48% Ramanathan[202]
71% Na[13]    59% Jardin[206]
72% Wendt[4]    61% Kyne[101]
87% Khanna[40]    61% Bartlett[207]
Severe disease Rare 16% Gogate[94] 8% Wendt[4]      3% McFarland[201]
12% Khanna[40]      3% Rubin[208]
21% Crews[12]      8% Bartlett[207]
27% Schwartz[176]      9% El Feghaly[182]
76% Pai[71] 16.4% Pepin[106]
   18% Wenisch[102]
   18% See[185]
   34% Khanna[209]
   47% Jardin[206]
   52% Ramanathan[202]
PMC 1 case Vidrine[95] 1% Lusk[36] 0.1% Wendt[4]   0.1% Wenisch[102]
1.6% Duleba[18]      1% McFarland[201]
4.9% Kim[98]
Toxic megacolon NR NR 1 case Castillo[99]   0.1% Wenisch[102]
Fulminant disease NR NR rare Qualman[203]      2% Dallal[108]
n = 4 Rivlin[204]      4% Sailhamer[210]
     6% van de Wilden[211]
Recurrent disease NR 28% de Souza[139] 10% Sandora[66] 18.8% Wenisch[102]
11% Wendt[4]    21% Vesteinsdottlir[73]
16.5% Crews[12]    22% Eyre[118]
17% Nylund[181]    22% Ramanathan[202]
17% Schwartz[176]    27% McFarland[121]
20% Khanna[40]    29% Wullt[122]
22% Nicholson[205]    29% Khanna[17]
24% Kim[98]    36% Drudy[212]
31% Morinville[100]    42% McFarland[89]
References are given by last name of first author and citation number in brackets. AAD: Antibiotic-associated diarrhea; CDI: Clostridium difficile infections; 
NR: Not reported; PMC: Pseudomembraneous colitis.
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initial episode of adult CDI cases is 6-12 d (Table 3), 
although delayed-onset (> 21 or 31 d post-discharge) 
has been reported in several studies ranging from 
10%-53% of CDI cases[45,86,87].
Time between recurrent episodes of CDI: The 
time between adult CDI recurrences has been reported 
in several studies, but there are no reports of this 
time interval in pediatric CDI. In 24 adults with C. 
difficile colitis, the mean time between episodes was 
69.6 ± 42.2 d, ranging from 3-32 d post-vancomycin 
treatment[88]. In another study of 209 adults with 
recurrent CDI, the mean time between episodes was 
69.6 ± 42 d[89]. Figueroa et al[90] reported the mean 
time to recurrence was 12.2 ± 6.4 d. Mean time to CDI 
recurrences in a mixed pediatric and adult population 
(aged 1-96 years old) was 42 d, and ranged from 
10-211 d[91].
Severity
Pediatric AAD severity: The definition of severity 
of disease for diarrhea has been well documented for 
adults, but is less standardized for pediatric cases. 
Most clinical trials define pediatric diarrhea as one to 
three abnormally loose stools per 24 to 48 h[19,20,21,92]. 
Additionally, stool frequency is more difficult to 
quantify in diaper-aged children. The reported mean 
duration for pediatric AAD is 3-9 d (Table 3)[63,76,93]. 
The severity of pediatric AAD ranges from mild, self-
limited diarrhea to moderate diarrhea (Table 3). In 
one study of 250 pediatric inpatients (5-12 years old) 
who developed diarrhea, most (82%) were not due 
to C. difficile, but 16% had severe diarrhea, 36% had 
abdominal pain and 11% reported vomiting[94]. If the 
symptoms of diarrhea are severe (> 10 movements/
d), pediatric AAD may lead to electrolyte disturbances 
and dehydration[94]. Few cases of pediatric antibiotic-
associated colitis or pseudomembranous colitis (PMC) 
have been reported. There is one case report of a 16 
year old girl who developed PMC not associated with C. 
difficile[95].
Adult AAD severity: Frequency of diarrhea, colitis 
and PMC associated with adult cases of AAD (not due 
to C. difficile) are infrequently reported. The mean 
duration of adult AAD is 1-22 d (Table 3). From one 
study, the mean duration adult AAD was four days 
while on antibiotics, but the mean duration was longer 
(18 d) if the cases were delayed-onset AAD[96].
Pediatric CDI severity: The range of symptoms 
for pediatric CDI is wide: children can develop mild-
moderate diarrhea or severe disease or recurrent 
episodes of CDI (Table 3). Most symptoms of pediatric 
CDI are mild-moderate diarrhea (23%-87%)[13,40]. 
The mean duration of pediatric CDI is not as well 
documented in the literature, but ranges 2-9 d based 
on limited reports (Table 3)[1,12,97]. A population-based 
surveillance study of pediatric CDI cases found 87% 
reported only diarrhea, 9% had severe CDI and 4% 
had severe CDI with complications[40]. Severe cases of 
pediatric CDI (defined variously as having > 2 severe 
indicators including fever, leukocytosis, requirement for 
ICU stay or surgery) have been reported in 8%-76% 
of cases (Table 3). Disease severity in pediatric CDI 
may be overestimated if adult criteria are used. In two 
studies reporting a high frequency of severe CDI in 
children, a re-assessment found the majority had low 
rates of morbidity and mortality and were successfully 
treated with standard antibiotic therapy[71,98]. Kim et 
al[98] defined severe pediatric CDI as having at least 
one complication (PMC, CDI-related surgery, intestinal 
perforation, toxic megacolon, or ICU stay) or ≥ 2 
laboratory/clinical indicators (elevated white blood cell 
count, or high albumin, or high creatinine, fecal blood 
or fever). Pai et al[71] defined severe pediatric CDI if 
any of the following were present: elevated white blood 
cell counts, rising serum creatinine, fever or signs 
of severe colitis. Hence new criteria for determining 
diarrhea severity in pediatric CDI are being studied. 
Infrequently, very severe forms of pediatric CDI have 
been reported. A case of CDI in a four year-old boy 
who had been treated with amoxicillin-clavulanic 
acid developed toxic megacolon[99]. Recurrences of 
pediatric CDI are common (10%-31% recurrence 
rates, as shown in Table 3), which may result in longer 
hospitalizations if the child is an inpatient[40,91,100]. Rates 
of recurrent CDI were found to be higher in children 
with severe CDI (31%) compared to a lower frequency 
(15%) if the child had mild-moderate CDI[98].
Adult CDI severity: Mild to moderate diarrhea is 
seen in 35-61% of adult CDI cases, while severe 
disease occurs less frequently (3%-41%), as shown in 
Table 3. In one study of 73 adult CDI cases, 18 (25%) 
had mild, self-limiting disease, 26 (36%) developed 
moderate diarrhea, 23 (31%) developed prolonged 
diarrhea and 6 (8%) developed complicated CDI[101]. 
The reported mean duration of adult CDI ranges from 
5-26 d (Table 3)[89,102,103]. Adults with severe CDI report 
abdominal pain and fever in addition to diarrheal 
symptoms[104]. Attributable mortality is significantly 
higher in adult patients with severe CDI compared 
to mild-moderate CDI (60% vs 28%, P = 0.046, 
respectively)[105]. A hypervirulent strain of C. difficile 
(NAP1/027/BI) was the predominant strain associated 
with outbreaks of CDI cases in 88 hospitals in 
Quebec Canada in 2003-2004 which were associated 
with twice the rate of severe CDI cases with higher 
mortality rates[106]. More recent surveillance studies 
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for endemic cases across 10 United States states also 
found a significantly elevated risk of severe CDI with 
the NAP1/027/BI strain[107]. Fortunately, the most 
severe forms of CDI (pseudomembraneous colitis, 
toxic megacolon or fulminant disease) are infrequently 
reported (1%-6%). Fulminant CDI is a systemic 
inflammatory syndrome that occurs infrequently, 
but typically requires colectomy and often results in 
death[108]. Although diarrhea is the hallmark of CDI, it 
may be absent in fulminant CDI, secondary to severe 
colonic dysmotility making fulminant colitis difficult to 
diagnose[109,110].
Recurrent CDI may occur in 19%-42% of adults 
after their initial episode of CDI has resolved, as shown 
in Table 3. As many as 10%-30% recur once after an 
initial CDI episode, 40% have two recurrences and 
50% of those continue to have multiple recurrences, 
which may occur over a period of several years[111]. 
The CDC estimates in the United States during 2011, 
483120 had initial CDI episodes and an estimated 
77000-232000 would have recurred, providing a 
conservative national estimate of 715000 cases of total 
CDI/year[9]. 
Comparison of clinical presentations of pediatric 
and adult AAD: The onset of pediatric AAD appears 
to be slightly quicker than adult cases of AAD and 
most pediatric AAD cases become symptomatic 
while the child is on antibiotics. In contrast, more 
cases of delayed-onset adult AAD cases are reported. 
However, whether this is a valid observation or due 
to the infrequent follow-up of children with antibiotic 
exposure is unknown. Most AAD cases are mild-
moderate both in pediatric and adults. Pediatric cases 
of AAD and CDI typically have a shorter duration than 
adult cases of AAD and CDI.
Comparison of the clinical presentation for 
pediatric vs adult CDI: The onset of CDI is fairly 
rapid for pediatric cases (3-10 d), while symptoms 
appear slightly later in adult CDI (2-15 d) and 
recurrences of adult CDI may appear within two 
months of the previous episode. Pediatric and adult 
cases of CDI are both typically mild-moderate disease 
and the frequency of severe disease is similar for 
pediatric and adult cases, despite the finding that 
the hypervirulent strain of BI/NAP1/027, which is 
associated with severe CDI, is rarely found in children. 
However, severe complications of CDI, especially 
fulminent CDI and PMC, are more common in adults 
and are rarely seen in pediatric CDI. Recurrent CDI is 
slightly more common in adults (averaging 25%) than 
for pediatric CDI (averaging 20%).
CONSEQUENCES OF INFECTION
Pediatric AAD consequences
The consequences of pediatric AAD for inpatients 
may include increased length of hospitalization 
and, for outpatients, parents may discontinue the 
inciting antibiotics due to the diarrhea, without fully 
treating the child for the inciting infection[76]. Other 
consequences of pediatric AAD have rarely been 
reported (Table 4).
Adult AAD consequences 
Prolonged length of stay and higher mortality rates 
have been reported for adult AAD cases[37,112]. Several 
studies have estimated that the cost of healthcare 
associated with adult AAD ranges from $1400-$1968/
person[113,114]. As with pediatric cases, development 
of AAD may also lead to premature discontinuation of 
antibiotic therapy, resulting in low cure rates[37].
Pediatric CDI consequences 
Consequences of pediatric CDI may include increased 
length-of-stays for inpatients, increased mortality, 
rates of surgery (colectomies), higher healthcare 
costs, and re-admissions to healthcare systems, as 
shown in Table 4. Crude mortality rates (1%-5%) and 
CDI attributable mortality rates (2-3%) are also low. 
Caution should be used when comparing mortality 
rates, as the observation periods vary from just 
during hospitalization stays[44,69], to 2-3 mo[71,115] to 6 
mo[12], or were not reported[14,100]. Even though the 
proportion of severe CDI can be higher in children, 
the requirement for colectomy is low (approximately 
1%) in mild-moderate CDI. However, the rate can be 
higher in cases of severe CDI. In one study of 151 
children with severe CDI, 8.6% required colectomies 
with a 50% associated mortality rate[116]. The median 
cost for healthcare for pediatric CDI is not trivial 
($19000-$32000/child). As an increase in incidence 
rates of pediatric CDI was observed from 1997-2006, 
there were also increases seen for costs for healthcare 
(averaging $20000/case) and an increased risk of 
colectomies[14]. In a survey of CDI in 22 Children’s 
hospitals in United States from 2004-2006, 26% of 
the 4895 inpatient CDI cases were children < 1 year 
old and 1.2% required colectomies. The all-cause 60-d 
mortality rate among pediatric patients was reported to 
be 4% in a study of 22 pediatric hospitals surveyed[115]. 
Costs for healthcare associated with pediatric CDI are 
generally > $20000 United States dollars. Additional 
increases in length of hospitalizations are also 
observed for pediatric CDI cases (Table 4) ranging 
from 4-23 additional days, which may explain the 
higher healthcare costs associated with this disease.
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Pediatric AAD Ref. Adult AAD Ref. Pediatric CDI Ref. Adult CDI Ref.
Premature stop 
of antibiotic 
therapy
Yes Damrongmanee[76]   4% Elseviers[37] NR NR
Dehydration NR 17% Elseviers[37]  75% Duleba[18] NR
Attributable 
mortality
NR NR    2% Despandi[169]   5.7% Dubberke[213]
2.2% Sammons[44]   5.7% Gravel[119]
   3% de Blank[69]   4.5% Tabak[117]
  6.3% Vesteinsdottir[73]
  6.9% Loo[57]
   15% McFarland[121]
   17% Pépin[58]
Crude mortality NR 3.6% Selinger[112]    1% Morinville[100]    10% Tabak[117]
   2% Nylund[14] 16.5% Wenisch[102]
3.8% Kim[115]    28% Bacci[120]
4.6% Crews[12]    35% Eyre[118]
   5% de Blank[69]    38% Dubberke[213]
5.4% Pai[71]
Colectomy NR NR 0.1% Wendt[4]   0.3% See[107]
0.9% Despandi[169]   0.7% Halabi[214]
0.9% Nylund[14]   1.2% Dallal[108]
   1% Pai[71]      2% McFarland[121]
1.2% Kim[115]   6.2% Muto[59]
  9.1% Jarvis[175]
Cost NR $1400 Song[113] $18900-$93000 Sammons[44] $3103 McFarland[89]
($/patient) $1968 Kamdeu[215] $28404 Despande[169] $3427-$33055 Kwon[10]
$31957 Nylund[14] $3427-99601 Dubberke[216]
$7179 Dubberke[217]
$116312 Dubberke[216]
$113533 Lawrence[124]
$23643 Tabak[117]
Length of stay 
(days additional 
stay)
NR 8.5 d Elseviers[37] 4 d Despande[169] 3 d Lawrence[124]
4 d Nylund[14] 4 d Dubberke[217]
6 d Sammons[44] 6 d Vesteinsdottir[73]
23d de Blank[69] 10 d Abdelsattar[218]
13 d Tabak[117]
14 d Crabtree[184]
16 d Zerey[193]
24 d McFarland[121]
Re-admissions NR 8% Pozzoni[160] NR    21% McFarland[121]
   39% Abdelsattar[218]
   52% Dubberke[213]
Adult CDI consequences
As with pediatric CDI, the consequences of adult CDI 
may also include increased mortality, higher rates of 
surgery (colectomies), higher healthcare costs, longer 
length-of-stays for inpatients and re-admissions to 
healthcare systems (Table 4). Reported crude mortality 
rates can be high (10%-38%), and CDI attributable 
mortality ranged from 6%-17%. As with pediatric 
studies, the follow-up for mortality ranges from only 
during hospitalization[117,118], to 30 d[57,58,102,119,120], to 
60 d[121], to 90 d[73], or to 6 mo[122]. Adult CDI was 
sufficiently severe to require colectomy in only 1%-9% 
of patients, but the mortality associated with this type 
of surgery is of clinical concern. A meta-analysis of 31 
studies of adults with CDI found overall, 1.1% needed 
a colectomy, but the rate increased to 30% if it was a 
severe case of CDI and post-colectomy mortality was 
exceedingly high (41%)[123]. Colectomy rates range 
from 0.3%-1.3% of CDI cases during outbreaks and 
1.9%-6.2% during endemic periods[10]. The healthcare 
costs of adult CDI ranges from $3427-$9960 for 
initial episodes of CDI and costs may reach as high 
as $33000 for recurrent cases[9,124]. The cost of adult 
CDI care was determined from 2012 HCUP data and 
ranged from $3427 to $33055/patient, depending if 
it is an initial or recurrent CDI case and the total CDI 
1 for initial CDI episodes only, 2 for recurrent CDI episodes only, 3 in intensive care unit. References are given by last name of first author and citation 
number in brackets. AAD: Antibiotic-associated diarrhea; CDI: Clostridium difficile infections; LOS: Length of stay; NR: Not reported.
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Pediatric AAD Ref. Adult AAD Ref. Pediatric CDI Ref. Adult CDI Ref.
Prevention
Enhanced 
infection control 
programs (% CDI 
reduced)
NR NR NR   67% You[219]
Antibiotic 
stewardship
NR NR NR   46% Wenisch[102]
(% CDI reduced)   66% Kallen[220]
Probiotics S. boulardii 
(pRR = 0.43)
McFarland[19] S. boulardii 
(pRR = 0.47)
McFarland[131] S. boulardii 
(pRR = 0.25)
McFarland[138] La+Lc+Lr 
(pRR = 0.21)
Johnson[137]
L. rhamnosus 
GG 
(pRR = 0.36)
McFarland[19] S. boulardii 
(pRR = 0.49)
Szajewska[132] S. boulardii 
(pRR = 0.25)
Szajewska[132] La+Lc+Lr 
(pRR = 0.21)
McFarland[138]
S. boulardii 
(pRR = 0.43)
Szajewska[132] La+Lc+Lr (pRR 
= 0.51)
Hempel[129] L. casei 
DN114001 
(pRR = 0.08)
McFarland[138]
L. rhamnosus 
GG (pRR = 
0.48)
Szajewska[132] L. rhamnosus GG 
(no)
Szajewska[132] S. boulardii 
(no)
Szajewska[132]
Treatment
Initial episode1
No treatment 
given or stop 
inciting antibiotic 
(% done)
NR   4% Elseviers[37] 0% Khanna[40]   10% Vensteinsdottir[73]
  4% Kim[98]
20% Duleba[18]   24% McFarland[121]
53% Pai[71]   53% Huang[65]
69% Gogate[94]
Oral rehydration 
therapy (% cured)
21% Shan[93] 17% Elseviers[37] NR NR
Metronidazole NR NR 31% Gogat[94]   75% Vesteindottlir[73]
(% cured) 69% Morinville[100]
82% Khanna[40]   84% Zar[145]
90 Pai[71]   86% Kim[221]
93% Kim[98]   94% Wenisch[222]
97% Duleba[18]
Vancomycin NR NR 83% Duleba[18]   91% Kim[221]
(% cured) 85% Jardin[206]   94% Cornely[141]
100% Khanna[40]   94% Wenisch[222]
  97% Zar[145]
100% Vesteindottlir[73]
Severe disease 
(% cured)
NR NR NR 97% vanco vs 
76% metro
Zar[145]
Probiotics 
(% cured)
NR S. boulardii 
(70%)
Ligny[140] NR S. boulardii 
(19%, ns)
McFarland[111]
Monoclonal 
antibodies
NR NR NR 93% 
(P = 0.07)
Lowy[146]
(% cured)
Recurrent disease1
Metronidazole NR NR NR 33% Wullt[223]
(% no further 
recurrences)
50% Surawicz[142]
58% McFarland[143]
80% Vesteindottlir[73]
Vancomycin NR NR NR 46% (10 d) McFarland[143]
(% no further 
recurrences)
55% Surawicz[142]
69% (taper) McFarland[143]
86% (pulse) McFarland[143]
100% Vesteindottlir[73]
Fidaxomycin NR NR NR 86% Cornely[147]
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(% no further 
recurrences)
Probiotics NR NR NR S. boulardii 
(65%)
McFarland[111]
(% no further 
recurrences)
S. boulardii 
with high 
dose vanco 
(83%)
Surawicz[142]
Fecal replacement 
therapy
NR NR NR 81% van Nood[224]
(% no further 
recurrences)
90% Cammatora[225]
costs for United States during 2012 ranged from $1-$6 
billion dollars[10]. For cases of adult HCFA-CDI cases, 
hospitalization was typically prolonged from 3-24 d 
(Table 4). For adults with CDI, the likelihood of being 
re-admitted to a healthcare facility is high (21%-52%), 
especially for patients with recurrent CDI.
Comparison of pediatric and adult consequences for 
AAD or CDI
A consequence of pediatric CDI may include 
dehydration, especially for younger children, unlike 
adults. Pediatric cases of CDI have lower mortality 
rates and less frequent rates of colectomies. However, 
for both pediatric and adult CDI, if symptoms are 
sufficiently severe to require colectomy, there are high 
mortality rates associated with this type of surgery. 
For inpatients, development of CDI is associated with 
longer lengths-of-stay and its associated increased 
cost of care.
PREVENTION
Prevention of Pediatric AAD
Prevention of AAD has traditionally relied on 
appropriate use of antibiotics, for instance, limiting the 
use of broad-spectrum antibiotics whenever possible. 
However, studies documenting the impact of these 
practices on pediatric AAD are lacking (Table 5). AAD 
results from the disruption of the normal, protective 
microbes in the intestine caused by unintended killing 
of non-pathogenic organisms by the antibiotics. 
Probiotics (living microbes, which when given at a 
sufficient dose, having a proven health benefit on the 
host) may be given at the same time as the antibiotics 
to prevent the development of AAD by helping to 
stabilize the normal microbiome[125]. Caution should 
be exercised to not give a bacterial strain of probiotic 
that is susceptible to the prescribed antibiotic. This is 
not of concern if the probiotic is a yeast strain. Of 17 
different types of probiotics tested for AAD, only a few 
strains have evidence-based efficacy for preventing 
pediatric AAD[126,127]. A meta-analysis of 22 randomized 
controlled trials testing various probiotics for the 
prevention of pediatric AAD found only two types of 
probiotics were significantly effective for pediatric AAD: 
a yeast, Saccharomyces boulardii CNCM I-745 (S. 
boulardii) (pooled RR = 0.43, 95%CI: 0.32-0.60) and 
a bacterial probiotic, Lactobacillus rhamnosus GG (LGG) 
(pooled RR = 0.36, 95%CI: 0.19-0.69)[19]. Other 
meta-analyses (Table 5) have confirmed this finding. 
Prevention of Adult AAD
Of 20 different probiotic types tested for the 
prevention of adult AAD, only a few have solid 
evidence for efficacy (Table 5). Videlock et al[128] 
pooled the results from 24 randomized controlled 
trials in adults and found in general, probiotics were 
effective in preventing AAD (pooled RR = 0.53, 
95%CI: 0.43-0.66), but they did not report which 
strain(s) were independently protective. Many meta-
analyses have reported combined data from a mixed 
population of adults and children or mixed types of 
probiotic strains[129,130]. One method to determine 
which probiotic strain is more effective is to only use 
data from one type of probiotic, or use sensitivity 
analysis to assess the effectiveness, grouping trials 
by the same strain of probiotic. A meta-analysis of 10 
randomized controlled trials using only S. boulardii 
for the prevention of adult AAD found significant 
efficacy for this probiotic (pooled RR = 0.47, 95%CI: 
0.35-0.63)[131]. Another meta-analysis pooled 15 trials 
and confirmed S. boulardii is effective for preventing 
adult AAD[132]. Hempel et al[129] conducted a meta-
analysis of probiotics for AAD, but pooled 62 trials (32 
different types of probiotics) that were a mixture of 
adult and pediatric populations and also mixed strains 
within some probiotic sub-groups. Their ‘Lactobacillus’ 
subgroup contained many different strains of 
Lactobacilli, but extracting three trials in adult patients 
and limiting the pooled results to one type of probiotic 
1Studies not reporting cure rates by initial or recurrent CDI cases were excluded. References are given by last name of first author and citation number 
in brackets. AAD: Antibiotic-associated diarrhea; CDI: Clostridium difficile infections; L.: Lactobacillus; La: L. acidophilus CL1285; Lc: L. casei LBC80R; Lr: L. 
rhamnosus CLR2; NR: Not reported; pRR: Pooled relative risk from meta-analysis; S.: Saccharomyces.
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mixture (L. casei and L. acidophilus and L. rhamnosus, 
“BioK+”), the pooled RR (pRR = 0.51, 95%CI: 
0.30-0.87) shows this mixture is significantly effective 
in preventing adult AAD, while other Lactobacilli 
probiotics were not effective. Xie et al[35] reviewed six 
trials for the prevention of AAD in elderly adults. Only 
one type of probiotic (B. licheniformis) in one trial was 
found to be effective, although the amount of evidence 
in the elderly population is extremely limited. Another 
meta-analysis pooled the data from six trials in adults 
randomized to either L. rhamnosus GG or placebo and 
did not find that this probiotic was effective to prevent 
adult AAD[133]. Although the data for the prevention 
of adult AAD by probiotics is extensive, the challenge 
is having sufficient numbers of clinical trials for each 
type of probiotic strain to allow a valid conclusion to be 
formulated.
Prevention of Pediatric CDI
The prevention of CDI is typically targeted at a 
common source of infection (healthcare facilities) and 
relies upon a multi-pronged approach of infection 
control programs, antibiotic stewardship and measures 
to support the host’s defenses. However, since 
HCFA pediatric CDI is not common, prevention of 
community-based CDI needs to rely on rational use 
of antibiotics and the use of probiotics. There are no 
studies of HCFA infection control programs in pediatric 
hospitals. The use of probiotics has been investigated 
in the pediatric population at risk. In one study of 283 
children receiving antibiotics for respiratory infections, 
only 0.7% randomized to S. boulardii CNCM I-745 
developed CDI compared to 5.6% of those given 
placebo, P = 0.04[93]. A meta-analysis of probiotics for 
the prevention of CDI was done, pooling the results 
of three pediatric trials and found probiotics reduced 
the incidence of pediatric CDI by 60% (pooled RR = 
0.40, 95%CI: 0.17-0.96)[134]. However, this analysis 
was limited by the small numbers of trials done 
per probiotic strain in pediatric patients. Another 
meta-analysis and systematic review of probiotics 
for pediatric CDI was also limited by the scarcity of 
controlled trials in this population. Although the pooled 
data from five randomized controlled trials showed 
probiotics, in general, were protective of pediatric CDI 
(pooled RR = 0.35, 95%CI: 0.13-0.92), four types of 
probiotics had no second, confirmatory trial, and only S. 
boulardii showed efficacy using data pooled from two 
trials (Table 5)[19]. 
Prevention of Adult CDI
Current guidelines recommend a bundled program of 
surveillance, contact precautions, CDI patient isolation, 
hand hygiene, use of disposable equipment when 
possible and environmental disinfection[2,135]. Rampant 
inappropriate antibiotic use was documented in the 
1990-2000’s in hospitalized patients and outpatients, 
and while antibiotic stewardship programs reduced this 
rate, one recent study still found 74% of antibiotics 
given to 126 inpatients with CDI were inappropriately 
prescribed[136]. There have been many studies showing 
the use of a multi-disciplinary infection program 
resulted in a decrease of adult CDI cases. One 
important foundation of these programs is the use of 
antibiotic stewardship oversight, which has been shown 
to reduce CDI rates in adult inpatients from 46%-66% 
(Table 5). Probiotics have also been tested to assess if 
they can be effective for preventing adult cases of CDI. 
A meta-analysis of 11 randomized controlled trials for 
the prevention of CDI tested five different types of 
probiotics and found only one mixture of probiotics (L. 
casei, L. acidophilus and L. rhamnosus, “BioK+”) had a 
significant preventive effect (pooled from three trials, 
RR = 0.21, 95%CI: 0.11-0.42), while the pooled data 
from four trials using S. boulardii was not effective (RR 
= 0.70, 95%CI: 0.29-1.69)[137]. The other four trials 
did not have confirmatory trials and were excluded. 
A more recent meta-analysis of 21 randomized trials 
testing probiotics for CDI found four types of probiotics 
were significantly effective for preventing CDI, but 
when pediatric trials were excluded, only two probiotic 
types were effective in adults: L. casei DN114001 
“Actimel” [pooled from two trials (RR = 0.08, 95%CI: 
0.01-0.63) and a mixture of L. acidophilus and L. 
casei and L. rhamnosus “BioK+” (pooled from three 
trials with four treatment arms, RR = 0.21, 95%CI: 
0.08-0.58)[138].
Comparison between prevention strategies for pediatric 
vs adult AAD and CDI
Prevention of pediatric and adult AAD may rely on 
rational use of antibiotics, but there have been no 
studies testing this intervention in pediatric or adult 
patients. There are studies of preventive strategies 
for adult CDI that include improved infection control 
programs focused on limiting C. difficile transmission 
at healthcare facilities, in addition to antibiotic 
stewardship programs to limit unnecessary or 
inappropriate antibiotic use. The data is supportive for 
the use of these programs to prevent adult CDI, but 
studies are lacking for pediatric populations. The use 
of preventive probiotics is supported by studies and 
children and adults seem to respond differently to the 
type of probiotic strain depending upon the outcome 
to be prevented. To prevent AAD, children responded 
better to S. boulardii or L. rhamnosus GG, while adults 
responded better to S. boulardii or the multi-strain 
mix of three Lactobacilli called ‘BioK+’. To prevent CDI, 
S. boulardii was effective in pediatric patients, while 
BioK+ or L. casei DN114001 worked well in preventing 
McFarland LV et al . Pediatric vs  adult AAD and CDI
3095 March 21, 2016|Volume 22|Issue 11|WJG|www.wjgnet.com
adult CDI cases.
TREATMENT
Treatment for pediatric AAD
Current treatment for pediatric AAD usually involves 
discontinuation or changing the type of the inciting 
antibiotic and giving oral rehydration therapy. As the 
etiology is typically only known for a proportion of 
the cases (approximately 1/3 is due to C. difficile), 
effective antibiotic treatment for AAD is limited. If the 
diarrhea is moderate-severe, oral rehydration therapy 
may be sufficient to assist spontaneous recovery[93].
Treatment for adult AAD
Current treatment for adult cases of AAD usually 
involves discontinuation or changing the type of 
the inciting antibiotic (Table 5). In one study of 743 
hospitalized adult patients in four Belgian hospitals 
who were given antibiotics, AAD developed in 
71 (9.6%), with only four patients positive for C. 
difficile. Of the 71, only 46 (65%) were treated for 
AAD: IV hydration (24%), patient isolation (22%), 
probiotics (20%), antidiarrheal medications (20%), 
metronidazole (6%), discontinuation of the inciting 
antibiotic (6%), or other antibiotics (2%)[37]. Very few 
randomized controlled trials have been done to treat 
adult cases of AAD, including those assessing the 
use of probiotics. One trial compared a mixture of L. 
casei and Bifidobacterium breve with placebo in 70 
adults with AAD and found no significant difference in 
the duration of AAD (4.9 d vs 4.5 d, respectively)[139]. 
Another study randomized 20 adults with mild AAD to 
either S. boulardii or placebo and found significantly 
more were cured with S. boulardii (70% vs 10%, P < 
0.01, respectively)[140]. No other trials for the treatment 
of adult AAD have been reported.
Treatment for pediatric CDI
Discontinuation or changing the type of the inciting 
antibiotic is still recommended as the first step for 
treating mild pediatric CDI, along with oral rehydration 
therapy if the diarrhea is severe[71]. For children with 
moderate CDI, empirical antibiotic treatment directed 
against C. difficile is recommended. The first choice 
of treatment is oral metronidazole (20-40 mg/kg/d), 
followed by oral vancomycin (40 mg/kg/d) given orally 
or by enema if they do not respond to metronidazole[1]. 
In one study of 4895 inpatient pediatric CDI cases, 
74% responded to metronidazole or vancomycin 
treatment[115]. Most studies have enrolled children with 
their first episode of CDI (Table 5) and show effective 
cure rates with either metronidazole (ranging from 
31%-97%) or vancomycin (ranging from 83%-100%). 
No studies on treatments have included children with 
recurrent CDI disease.
Treatment for adult CDI
Treatment for the initial episode of adult CDI typically 
relies upon one of three antibiotics, while treatment of 
recurrent CDI may require adjunctive use of probiotics 
or immune stimulators. Once CDI has been diagnosed 
in adults, treatment with antibiotics directed against C. 
difficile is recommended (metronidazole or vancomycin 
or fidaxomicin)[2,28,141]. For mild to moderate CDI or 
for initial episodes of CDI, the recommended dose of 
metronidazole is 500 mg, three times daily and for 
vancomycin the dose is 125 mg four times daily, but 
if there is no response or if the CDI is severe, higher 
doses of vancomycin can be used (up to 2 g/d)[2,142,143]. 
Failure to respond to the antibiotic used within 5-7 
d should prompt the switch to the other type of 
antibiotic. A meta-analysis of 15 treatment trials for 
adult CDI found vancomycin has a higher cure rate 
(mean 88% ± 9.1%) compared to metronidazole (76% 
± 11.3%) and a lower rate of CDI recurrences (13% 
± 9.9% and 31% ± 44%, respectively)[144]. For severe 
cases of adult CDI, treatment with vancomycin has 
been found to be more effective than metronidazole 
(97% cured vs 76% cured, respectively)[145]. 
Treatment recommendations vary according to 
whether the CDI episode is an initial episode, or if the 
patient has recurrent CDI disease and Table 5 presents 
the effectiveness of various treatments for studies that 
provide data separately for initial vs recurrent CDI 
disease. Vancomycin has slightly higher cure rates 
(91%-100%) for adults with initial CDI compared to 
metronidazole (75%-94%). Fidaxomicin was found to 
be equivalent to vancomycin for the initial episode of 
CDI in adult patients[141]. One study using monoclonal 
antibodies against C. difficile showed a trend (P = 0.07) 
for better cure rates (93%) compared to placebo (82%) 
for the initial episode of CDI[146]. 
From 20%-60% of adults treated with antibiotics 
have at least one recurrence of CDI, and many 
suffer from repeated recurrences that may occur 
over a period of years[143]. Effective treatments for 
adult recurrent disease have included vancomycin 
(55%-100% cured), while metronidazole seems to 
be less effective (50%-80% cured). Fidaxomicin was 
shown to successfully treat recurrent CDI, when it 
reduced the recurrence rate to 14% compared to 
26% in vancomycin[147]. The first recurrence should be 
treated with a repeated 10-d course of vancomycin, 
while the subsequent recurrences are recommended 
to be treated with pulsed or tapered vancomycin 
regimes or use an adjunctive probiotic[2]. In one study 
of 163 adults with recurrent CDI, higher cure rates 
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were noted for treatment with vancomycin pulse (86%) 
or vancomycin taper (69%) compared to a single 10-d 
vancomycin (46%) or metronidazole (58%) regime[143]. 
By the end of therapy, vancomycin was more effective 
at clearing C. difficile culture and/or toxins (89%) 
than metronidazole (59%, P < 0.001). The evidence 
for probiotics to treat adult CDI is limited by the 
small number of randomized controlled trials for each 
probiotic strain. One type of probiotic, S. boulardii, has 
two trials which provide evidence that this probiotic 
may be effective for preventing recurrences of CDI in 
adults, especially if combined with high dose (2 g/d) 
vancomycin[131,148]. Fecal microbial transplants (FMT) 
have been tested to treat adults with recurrent CDI 
and this method uses stool infusions from healthy 
donors containing a mixture of microbes[149]. Two 
controlled trials found significantly higher cure rates 
for those patients receiving FMT (81% and 90%) 
compared to the control patients (Table 5). Many other 
investigational treatments are being tested for adult 
CDI, including passive immunization using monoclonal 
antibodies and vaccines to C. difficile toxins, but the 
evidence is not yet conclusive[150]. 
Comparison between treatments for pediatric vs adult 
AAD and CDI
The paucity of studies evaluating treatments for 
pediatric and adult AAD limits any conclusions, except 
to discontinue or switch the inciting antibiotic and use 
of oral rehydration therapy to prevent dehydration 
in children. To treat the initial episode of CDI, 
discontinuing the inciting antibiotic is more commonly 
seen in the pediatric patient compared to adults. 
Pediatric patients with initial CDI appear to respond 
slightly better to metronidazole, while adults respond 
slightly better to vancomycin. The choice should be 
balanced against the side-effects and toxicities of 
each antibiotic. For recurrent disease, the only studies 
that provided separate cure rates for metronidazole, 
vancomycin or fidaxomicin were in adult patients 
with recurrent CDI. Treatment with high doses of 
vancomycin, use of pulsed or tapered regimes of 
vancomycin, fidaxomicin or adjunctive use of some 
probiotic strains or FMT may be beneficial for adults 
with recurrent disease, but whether these treatments 
are effective in children with recurrent CDI has not 
been established.
CONCLUSION
This is the first comprehensive exploration comparing 
the similarities and differences of pediatric vs adult 
AAD and CDI. In summary, some of the major 
differences between pediatric and adult AAD and CDI 
relate to incubation periods, severity of the disease 
and treatment strategies. Most pediatric AAD/CDI 
cases become symptomatic while on antibiotics; in 
contrast, most adult cases have delayed-onset of 
symptoms that appear after the antibiotics have been 
discontinued and before the normal colonic microbiome 
has recovered. Pediatric CDI cases have lower 
mortality rates and fewer complications than adult CDI 
cases. Community acquired cases of CDI are more 
common in children, while most cases of adult CDI are 
associated with healthcare facilities. Adult CDI has a 
more diverse risk factor profile (more co-morbidities, 
types of hospital exposures, disruptive medications, 
etc.) than pediatric CDI, but both populations share 
increased risk for antibiotic exposure as a major risk 
factor. Pediatric CDI responds better to metronidazole, 
while adult CDI cases favor vancomycin. Recurrent CDI 
is reported more frequently in adults and treatment 
relies on a combination of antibiotic therapy and 
measures to restore the normal colonic microbiota 
including the use of probiotics or FMT. 
Gaps in the knowledge base
By reviewing the literature, it became apparent there 
are several gaps in our knowledge about AAD and CDI. 
While national and global surveillance programs have 
been started for CDI to document incidence and trends 
over time, these programs have not been established 
for AAD. Basic demographic information (age, gender 
and race) and the spectrum of disease severity are 
infrequently reported for pediatric and adult cases of 
AAD. In addition, as the character of the intestinal 
microbiome shifts widely during the early childhood 
periods (neonatal, infant, pre-school, school-age, etc.) 
as children change nutritional status (bottle-fed, solid 
food, etc.) and are exposed to different environments 
(day-care, schools, etc.), a finer delination of AAD and 
CDI disease data by age categories might illuminate 
how children respond to these diseases as these other 
types of life-factors change. Broadly pooling data by 
a ‘pediatric’ classification may be masking some age-
related responses. Sources of non-CDI associated 
AAD are difficult to determine due to the lack of 
documentation for specific etiologies. The lack of 
reported complications of pediatric and adult AAD may 
be due to either a true lack of disease progression, or 
due to the lack of adequate follow-up times for studies 
involving AAD. The lack of reported treatment studies 
for AAD and pediatric CDI requires further studies. It 
also would be interesting to determine if pediatric CDI 
is a risk factor when these children grow into adults.
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